Jose Avitia, MD
Hematology & Oncology · Albuquerque, NMNPI 1669511663
Payments from drug & device makers
Across 306 payments — averaging $1806.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$260K
- AstraZeneca$251K
- Bristol Myers Squibb$30K
- Daiichi Sankyo Inc.$4K
- Novartis$2K
- E.r. Squibb & Sons, L.L.C.$2K
- plus $5K from 25 others
What the payments were for
- Consulting fees$8,16171%
- Speaking & faculty fees$1,20010%
- Food & beverage$1,79716%
- Education$3333%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 219 | $259,920 |
| AstraZeneca | 5 | $250,922 |
| Bristol Myers Squibb | 2 | $30,253 |
| Daiichi Sankyo Inc. | 8 | $3,639 |
| Novartis | 3 | $1,694 |
| E.r. Squibb & Sons, L.L.C. | 3 | $1,677 |
| Rigel Pharmaceuticals, Inc. | 1 | $1,200 |
| Merck | 14 | $1,001 |
| Janssen Scientific Affairs, LLC | 1 | $954 |
| Astellas Pharma US Inc | 12 | $463 |
| Pfizer | 7 | $171 |
| ASD Specialty Healthcare, LLC | 2 | $144 |
| AbbVie | 7 | $139 |
| Lilly USA, LLC | 1 | $83 |
| Genentech USA, Inc. | 1 | $65 |
| Johnson & Johnson | 3 | $65 |
| Karyopharm Therapeutics Inc. | 3 | $54 |
| Exelixis Inc. | 1 | $32 |
| Sanofi | 1 | $31 |
| AVEO Pharmaceuticals, Inc. | 1 | $28 |
| Beigene USA, Inc. | 1 | $27 |
| Genmab U.S., Inc. | 1 | $27 |
| Seagen Inc. | 1 | $26 |
| G1 Therapeutics, Inc. | 1 | $24 |
| Epizyme, Inc. | 1 | $19 |
| Coherus Oncology, Inc. | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Taiho Oncology, Inc. | 1 | $17 |
| Axonics, Inc. | 1 | $14 |
| Mirati Therapeutics, Inc. | 1 | $13 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$552,751 in reported general payments places this provider in the 85th percentile of 54 hematology & oncology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NubeqaDarolutamide | 36 | $488,744 |
| XtandiEnzalutamide | 34 | $440,630 |
| Abiraterone Acetate | 307 | $374,687 |
| PomalystPomalidomide | 15 | $337,727 |
| InlytaAxitinib | 20 | $278,353 |
| ErleadaApalutamide | 22 | $217,615 |
| IbrancePalbociclib | 13 | $208,820 |
| Lenalidomide | 13 | $197,805 |
| XareltoRivaroxaban | 52 | $53,795 |
| Pazopanib Hcl | 13 | $48,819 |
| OrgovyxRelugolix | 18 | $47,627 |
| EliquisApixaban | 61 | $35,938 |
| Imatinib Mesylate | 19 | $4,146 |
| Prednisone | 241 | $1,799 |
| Hydroxyurea | 58 | $1,748 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerInlyta, Ibrance, Eliquis | $171 | $523,11194 claims |
| BayerNubeqa | $259,920 | $488,74436 claims |
| Astellas Pharma US IncXtandi | $463 | $440,63034 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $954 | $374,687307 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $1,677 | $337,72715 claims |
| Johnson & JohnsonErleada, Xarelto | $65 | $271,41174 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 54 hematology & oncology providers in New Mexico.
Other hematology & oncology in Albuquerque
- Ursa Brown GlabermanAlbuquerque$5M
- Neda Hashemi SadraeiAlbuquerque$1.6M
- Olivier RixeAlbuquerque$1.6M
- Emrullah YilmazAlbuquerque$1.3M
- Erika MaestasAlbuquerque$880K
- Jacklyn NemunaitisAlbuquerque$351K
- Barbara McAnenyAlbuquerque$326K
- Zoneddy DayaoAlbuquerque$319K
- Yara AbdouAlbuquerque$294K
- Scott HerbertAlbuquerque$268K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.